Aaron Cranston Tablet Image Aaron Cranston Mobile Image
Mobile Gradient

Aaron Cranston

Aaron Cranston Tablet Image Aaron Cranston Mobile Image
Mobile Gradient

Aaron Cranston

 

Aaron joined Almac Discovery in 2016 and has responsibility for translational research activities including key external research collaborations.  Aaron has over 20 years of experience in preclinical oncology and left Mission Therapeutics, where he was Head of Pharmacology for the deubiquitylating enzyme (DUB) specialist, to join Discovery.  Aaron has also previously worked for PRECOS, a specialist oncology CRO and KuDOS Pharmaceuticals (acquired by AstraZeneca).  At KuDOS, he made notable contributions to the PARP inhibitor programme which led to olaparib (Lynparza┬«), now a first-in-class marketed treatment for BRCA-mutant ovarian cancer.

Click to Read More

Aaron carried out his post-doctoral research at the Kimmel Cancer Center, Philadelphia and the University of Cambridge.

He has a Ph.D in Cancer Genetics from QueenÔÇÖs University.

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies